Education
About Us
Working with TipRanks
Follow Us
BioRestorative Therapies (BRTX)
NASDAQ:BRTX
Earnings Data
Report Date
Mar 26, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.38Last Year’s EPS
-0.2Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The earnings call highlighted significant milestones in the company's clinical and commercial development, such as the Fast Track designation for BRTX-100 and a new patent for ThermoStem. However, these were counterbalanced by a sharp revenue decline and increased net loss compared to the previous year. Despite the financial setbacks, the overall sentiment is cautiously optimistic with strategic developments and a strengthened financial position.Company Guidance
Fast Track Designation for BRTX-100
The BRTX-100 program for chronic lumbar disc disease was granted Fast Track designation by the FDA, a major milestone that enables closer collaboration with the FDA for potential accelerated Biologic License Application (BLA) approval.
ThermoStem Patent Milestone
The Japanese Patent Office issued a notice of allowance for BioRestorative Therapies' ThermoStem platform, providing broad protection terms for allogeneic, off-the-shelf brown adipose-derived stem cell technology.
Strengthening Commercial Infrastructure
BioRestorative Therapies has rebuilt and strengthened its commercial infrastructure, including supply chain, sales coverage, and distribution, with the appointment of Crystal Romano as Global Head of Commercial Operations.
Recent Financing Success
The company closed a fully subscribed financing priced above market, strengthening the balance sheet with gross proceeds of approximately $1.1 million.
BRTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
BRTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 12, 2025 | $1.38 | $1.25 | -9.42% |
Aug 12, 2025 | $1.47 | $1.50 | +2.04% |
May 14, 2025 | $1.71 | $1.67 | -2.34% |
Mar 27, 2025 | $1.83 | $1.81 | -1.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does BioRestorative Therapies (BRTX) report earnings?
BioRestorative Therapies (BRTX) is schdueled to report earning on Mar 26, 2026, After Close (Confirmed).
What is BioRestorative Therapies (BRTX) earnings time?
BioRestorative Therapies (BRTX) earnings time is at Mar 26, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is BRTX EPS forecast?
BRTX EPS forecast for the fiscal quarter 2025 (Q4) is -0.38.